Chemizon to Provide Array BioPharma with Chemistry Services
News Oct 18, 2007
Chemizon has announced that it has signed an agreement with Array BioPharma to provide Array with various medicinal chemistry services including chemical synthesis and new route research. Chemizon’s technical team will support Array’s internal chemistry capabilities, providing Array with a reliable, external partner to meet aggressive timelines.
“Chemizon is a professional organization with high caliber scientists and excellent facilities. We expanded our relationship with Chemizon to rapidly and cost-effectively progress our internal drug discovery programs,” said Kevin Koch, Ph.D., President and Chief Scientific Officer, Array BioPharma.
“Array is a world class drug discovery company and we are delighted that they chose Chemizon as their medicinal chemistry partner,” said Tony Piscopio, Ph.D., the Chairman and CEO of Chemizon Inc. “In the past 20 months, Chemizon has made rapid strides, both in terms of people and capabilities. The principal reason for this growth has been due to satisfied partners like Array.”
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE